Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Lutavit A/D3 1000/200 NXT provides a combination of vitamin A and vitamin D3 in one formulation
Subscribe To Our Newsletter & Stay Updated